Mayo Clinic | Strategic Alliance Partners

Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]

Only 17% of patients who received 1 g/kg of intravenous immunoglobulin every 4 weeks or more experienced disease relapse compared with 50% of those treated with lower or less frequent dosing.

The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology provided insight on projects they feel are needed to advance the care of patients with migraine-related disorders. [WATCH TIME: 4 minutes]

The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology discussed some of the key research needs for migraine care going forward. [WATCH TIME: 3 minutes]

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

Annualized attack rate was reduced to 0.08 attacks per year after the first administration of inebilizumab, similar to those who were not previously exposed to rituximab.

An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.

During the double-blind treatment phase, rates of hypertension AEs were low for the placebo and erenumab 70- and 140-mg treatment groups, as well as during open-label erenumab treatment.

Between PREVENT baseline and end, mean EDSS and Hauser Ambulation Index scores improved with eculizumab (Soliris; Alexion) monotherapy and deteriorated with placebo alone.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed unmet needs of care for patients with neuromyelitis optica spectrum disorder.

The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided context on challenges within the NMOSD space and what’s next following the first-approved therapies.

The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the most notable recent advances that has propelled care for patients with NMOSD.

The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.

The professor of neurology at Mayo Clinic College of Medicine discussed which biomarkers have shown the most relevancy in NMOSD and which deserve more attention.

The professor of neurology at Mayo Clinic College of Medicine discussed several areas within the neuromyelitis optica spectrum disorder that are of interest for ongoing and new research efforts.

The professor of neurology at Mayo Clinic College of Medicine discussed the 3 currently FDA-approved agents for NMOSD and other agents currently within the clinical pipeline.

The professor of neurology at Mayo Clinic College of Medicine discussed lesser-known facets of NMOSD and how the disease evolves over time.

The professor of neurology at the Mayo Clinic College of Medicine detailed the strides made in recognizing NMOSD as its own disease, along with specific biomarkers that identify it.

Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).

Complete resolution of the index T2-lesion and resolution of all T2 lesions occurred most often in patients with MOGAD rather than AQP4-IgG-NMOSD or MS.

Instead of a smooth-contoured, thin, and regular ring or arc typically seen, pattern 3 patients had atypical rings such as irregularly thick rings and arcs.

Chaired by Brian G. Weinshenker, MD, the presentations also feature Mayo Clinic experts W. Oliver Tobin, MBBCh, BAO, PhD; Jessica Stulc, MD, MPH; and Orhun H. Kantarci, MD. [WATCH TIME: 1 hour, 30 minutes]

Total lesion volume and index lesion-related severity correlated with EDSS scores and cognitive performance, while volumetric cortical and subcortical gray matter correlated less strongly.

Identified by Mayo Clinic investigators, the protein-coding gene SERPINA5 was found to be associated with tau expression, characteristic of Alzheimer disease pathology.

The professor of neurology at Mayo Clinic detailed the next steps in understanding more about the impact social determinants of health have on epilepsy care.

African Americans are not only at increased risk of having a stroke, but they're also at increased risk of being debilitated by or dying from a stroke.

Understanding the signs and symptoms stroke during National Stroke Awareness Month.

Lightheadness, loss of balance, vision changes, and abnormal eye movements led to the discovery of cancer in one specific patient.

The professor of neurology at Mayo Clinic discussed the effects social determinants of health can have on epilepsy treatment outcomes and where research needs to turn to next.